MEK1/2 Inhibitor (U0126) and PI3K Inhibitor (LY294002) Suppress Herpes Simplex Virus Type 1 Replication by Targeting MAPK/ERK1/2 and PI3K/AKT Signaling Pathways: Implications for Oral Health and Translational Control of Orolabial HSV-1 Infection
Targeting host signaling bottlenecks with U0126 and LY294002 offers a dual-pronged antiviral strategy against HSV-1 by dismantling the ERK/AKT axis critical for replication and inflammatory amplification. These findings position MEK1/2 and PI3K as promising therapeutic nodes for managing cutaneous HSV-1 infections. This host-directed dual-pathway inhibition may therefore help reduce recurrent orolabial HSV-1 lesions.
Authors
- Zahra Zahid Piracha (ORCID: https://orcid.org/0000-0001-8973-9773)
- Dilber Uzun Ozsahin (ORCID: https://orcid.org/0000-0002-3873-1410)
- İlker Özsahin
- Zhanping Ren
- Wei Meng
- Yongwei Tao
- Umar Saeed
Institutions
- Foundation University Islamabad (PK)
- Korea University (KR)
- University of Sharjah (AE)
- International Medical Research (Germany) (DE)
- Hulunbuir University (CN)
- Korea University (JP)
- Near East University (CY)
- Széchenyi István University (HU)
- Xi'an Jiaotong University (CN)
Publication Details
- Journal
- Iranian journal of pharmaceutical research
- Published
- 2026-01-04
- DOI
- https://doi.org/10.5812/ijpr-164639
- Primary Topic
- Herpesvirus Infections and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00